Published • loading... • Updated
White House to Announce Drug Pricing Deal with Regeneron
Regeneron will cut Medicaid prices and list Praluent on TrumpRx, while committing nearly $10 billion to U.S. production, Reuters reported.
- On Thursday, President Donald Trump announced a pricing agreement with Regeneron Pharmaceuticals, the final company to join his 'Most Favored Nation' initiative. The deal includes lower Medicaid prices and lists the cholesterol drug Praluent for $225 on TrumpRx.
- This agreement completes the administration's yearlong effort to align United States drug prices with those in developed nations, involving 17 pharmaceutical companies representing 80% of the branded drug market ahead of November's midterm elections.
- Regeneron committed nearly $10 billion to domestic manufacturing and $27 billion in research, development and manufacturing in the U.S. The Food and Drug Administration approved the company's gene therapy, Otarmeni, for rare hearing loss and will provide it free to eligible patients.
- During the Oval Office event, Trump told the mother of 2-year-old Travis Smith, "He was 100% deaf, but he took this miracle cure and now he can hear his mom, Sierra, say, 'I love you.'" Sierra said the treatment transformed her son.
- Critics note the administration has not made contract details public; Health Secretary Robert F. Kennedy Jr. declined to disclose terms, citing proprietary information. Some analysts question the deal's impact, noting Medicaid patients already pay low co-payments.
Insights by Ground AI
Podcasts & Opinions
59 Articles
59 Articles
Trump unveils deal with Regeneron to lower its drug prices for Medicaid
President Donald Trump on Thursday announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House's signature drug pricing initiative.
·Washington, United States
Read Full Article
‘Even the fake news has to be impressed’: Trump announces new plan to cut prices of pharmaceuticals * WorldNetDaily * by Bob Unruh
Source link President Donald Trump on Thursday announced a new program to cut the costs of pharmaceuticals for consumers, a problem he repeatedly has worked to address while in the White House. The new plan, according to a report from legacy wire service AP, is that drugmaker Regeneron will lower the cost of its products
Coverage Details
Total News Sources59
Leaning Left19Leaning Right16Center20Last UpdatedBias Distribution36% Center
Bias Distribution
- 36% of the sources are Center
36% Center
L 35%
C 36%
R 29%
Factuality
To view factuality data please Upgrade to Premium
